PITTSBURGH — Mylan N.V. announced the U.S. launch of mesalamine delayed-release tablets USP, 1.2 g, a generic version of Shire’s Lialda Delayed-Release Tablets. Mylan Pharmaceuticals received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the induction of remission in patients with active,
MORGANTOWN, W.Va. — Global pharmaceutical company Mylan and West Virginia University (WVU) today announced a 10-year collaboration, supported by a $5 million charitable contribution from Mylan, to develop and implement a program that will expose children across West Virginia to STEM (Science, Technology, Engineering and Math) and challenge traditional thinking about how STEM skills can be
HERTFORDSHIRE, England and PITTSBURGH — Global pharmaceutical company Mylan N.V. announced the U.S. launch of Drospirenone and Ethinyl Estradiol tablets USP, 3 mg/0.02 mg, a generic version of Bayer’s Yaz tablets. Mylan Pharmaceuticals received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which
HERTFORDSHIRE, England and PITTSBURGH and NESS ZIONA, Israel — Mylan N.V. and Mapi Pharma Ltd. announced that the two companies will team on the development and commercialization of GA Depot, a long-acting Glatiramer Acetate product. Mylan is acquiring global marketing rights to the product. GA Depot is a proposed once-monthly injection for the treatment of
HARTFORD, Conn. — Twenty states have accused six generic drug manufacturers of price fixing. The states’ attorneys general also said their lawsuit, filed in federal court here, may be just the start of a much broader legal action. The suit charges that the drug makers, led by New Jersey-based Heritage Pharmaceuticals, conspired to artificially elevate
